small molecule

ACZONE

DAPSONE

Loss of exclusivityloss of exclusivity
CompanyAlmirallSee this company's full patent-cliff portfolio

Drug detail

Brand nameACZONE
Active ingredientDAPSONE
Strength5%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalJuly 2005
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ACZONE patent cliff — loss of exclusivity — | CliffBio